Factor VIII therapy for hemophilia A: current and future issues

References

• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19(1):e1-47
   PubMed Web of Science ®Google Scholar
• National Heart Lung and Blood Institute. Diseases and Conditions Index. What is hemophilia? Available from: www.nhlbi.nih.gov/health/dci/Diseases/hemophilia/hemophilia_what.html [Last accessed 9 December 2009]
   Google Scholar
• White GC, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85(3):560
   PubMed Web of Science ®Google Scholar
• National Hemophilia Foundation. History of bleeding disorders. Available from: www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=178&contentid=6 [Last accessed 23 June 2012]
   Google Scholar
• Scharrer I, Becker T. Products used to treat hemophilia: evolution of treatment for hemophilia A and B. In: Lee CA, Berntorp EE, Hoots WK, editors. Textbook of hemophilia. Blackwell Publishing Ltd; Malden, MA, USA: 2005. p. 131-5
   Google Scholar
• Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 1990;323(26):1800-5
   PubMed Web of Science ®Google Scholar
• Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984;312(5992):337-42
   PubMed Web of Science ®Google Scholar
• Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984;312(5992):326-30
   PubMed Web of Science ®Google Scholar
• Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984;312(5992):330-7
   PubMed Web of Science ®Google Scholar
• Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984;312(5992):342-7
   PubMed Web of Science ®Google Scholar
• Wion KL, Kelly D, Summerfield JA, et al. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985;317(6039):726-9
   PubMed Web of Science ®Google Scholar
• Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998;92(11):3983-96
   PubMed Web of Science ®Google Scholar
• Shovlin CL, Angus G, Manning RA, et al. Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension. PLoS One 2010;5(2):e9154
   PubMedGoogle Scholar
• Church WR, Jernigan RL, Toole J, et al. Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. Proc Natl Acad Sci USA 1984;81(22):6934-7
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Brackmann HH, Hanfland P, Schwaab R. Molecular genetics in haemophilia A. Vox Sang 2000;78(Suppl 2):33-8
   PubMedGoogle Scholar
• Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988;263(13):6352-62
   PubMed Web of Science ®Google Scholar
• Fay PJ. Factor VIII structure and function. Int J Hematol 2006;83(2):103-8
   PubMed Web of Science ®Google Scholar
• Vlot AJ, Koppelman SJ, van den Berg MH, et al. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995;85(11):3150-7
   PubMed Web of Science ®Google Scholar
• Saenko EL, Shima M, Sarafanov AG. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex. Trends Cardiovasc Med 1999;9(7):185-92
   PubMed Web of Science ®Google Scholar
• Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004;18(1):1-15
   PubMed Web of Science ®Google Scholar
• Nemerson Y. Tissue factor and the initiation of blood coagulation. Adv Exp Med Biol 1987;214:83-94
   PubMedGoogle Scholar
• Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977;74(12):5260-4
   PubMed Web of Science ®Google Scholar
• Butenas S, DiLorenzo ME, Mann KG. Ultrasensitive fluorogenic substrates for serine proteases. Thromb Haemost 1997;78(4):1193-201
   PubMed Web of Science ®Google Scholar
• Brass LF. Thrombin and platelet activation. Chest 2003;124(3 Suppl):18S-25S
   PubMed Web of Science ®Google Scholar
• Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003;101(1):20-30
   PubMed Web of Science ®Google Scholar
• Fay PJ. Subunit structure of thrombin-activated human factor VIIIa. Biochim Biophys Acta 1988;952(2):181-90
   PubMedGoogle Scholar
• Nesheim ME, Taswell JB, Mann KG. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem 1979;254(21):10952-62
   PubMed Web of Science ®Google Scholar
• Cawthern KM, van ’t Veer C, Lock JB, et al. Blood coagulation in hemophilia A and hemophilia C. Blood 1998;91(12):4581-92
   PubMed Web of Science ®Google Scholar
• HAMSTeRS. The Haemophilia A mutation, structure test and resource site. Available from: http://hadb.org.uk [Last accessed 1 March 2013]
   Google Scholar
• Hallden C, Knobe KE, Sjorin E, et al. Investigation of disease-associated factors in haemophilia A patients without detectable mutations. Haemophilia 2012;18(3):e132-7
   Web of Science ®Google Scholar
• Pezeshkpoor B, Rost S, Oldenburg J, El-Maarri O. Identification of a third rearrangement at Xq28 that causes severe hemophilia A as a result of homologous recombination between inverted repeats. J Thromb Haemost 2012;10(8):1600-8
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006;12(Suppl 6):15-22
   PubMedGoogle Scholar
• Becker J, Schwaab R, Moller-Taube A, et al. Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies. Am J Hum Genet 1996;58(4):657-70
   PubMed Web of Science ®Google Scholar
• Rossiter JP, Young M, Kimberland ML, et al. Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. Hum Mol Genet 1994;3(7):1035-9
   PubMed Web of Science ®Google Scholar
• Schwarz J, Astermark J, Menius ED, et al. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia 2013;19(1):113-18
   PubMed Web of Science ®Google Scholar
• Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009;360(16):1618-27
   PubMed Web of Science ®Google Scholar
• Ljung R, Petrini P, Nilsson IM. Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand 1990;79(2):196-200
   PubMed Web of Science ®Google Scholar
• Kling S, Ljung R, Sjorin E, et al. Origin of mutation in sporadic cases of haemophilia-B. Eur J Haematol 1992;48(3):142-5
   PubMed Web of Science ®Google Scholar
• Leuer M, Oldenburg J, Lavergne JM, et al. Somatic mosaicism in hemophilia A: a fairly common event. Am J Hum Genet 2001;69(1):75-87
   PubMed Web of Science ®Google Scholar
• Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Treatment of hemophilia monograph series, no. 34; September 2004. Available from: http://www1.wfh.org/publication/files/pdf-1178.pdf
   Google Scholar
• Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995;74(6):1402-6
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012;119(12):2922-34
   PubMed Web of Science ®Google Scholar
• Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998;79(4):762-6
   PubMed Web of Science ®Google Scholar
• Carcao MD, van den Berg HM, Ljung R, Mancuso ME; PedNet, the Rodin Study G. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood 2013;121(19):3946-52, S3941
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365(25):2357-65
   PubMed Web of Science ®Google Scholar
• High KA. The gene therapy journey for hemophilia: are we there yet? Hematology Am Soc Hematol Educ Program 2012;2012:375-81
   PubMed Web of Science ®Google Scholar
• DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002;8(3):280-7
   PubMed Web of Science ®Google Scholar
• Brackmann HH, Wallny T. Immune tolerance: high-dose regimen. In: Rodriguez-Merchan EC, Lee CA, editors. Inhibitors in patients with hemophilia. Blackwell Science, Ltd; Oxford, England: 2002. p. 45-8
   Google Scholar
• Astermark J, Oldenburg J, Escobar M, et al. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005;90(7):924-31
   PubMed Web of Science ®Google Scholar
• Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010;16(102):66-70
   PubMedGoogle Scholar
• Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121(20):4046-55
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Navarrete AM, Andre S, et al. Dynamics of factor VIII interactions determine its immunological fate in hemophilia A. Blood 2008;112(2):240-9
   PubMed Web of Science ®Google Scholar
• Brackmann HH, Schwaab R, Effenberger W, et al. Antibodies to factor VIII in hemophilia A patients. Vox Sang 2000;78(Suppl 2):187-90
   PubMedGoogle Scholar
• Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004;77(2):187-93
   PubMed Web of Science ®Google Scholar
• Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000;60(3):547-54
   PubMed Web of Science ®Google Scholar
• Pergantou H, Matsinos G, Papadopoulos A, et al. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006;12(3):241-7
   PubMed Web of Science ®Google Scholar
• Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006;12(2):154-62
   PubMed Web of Science ®Google Scholar
• Astermark J, Altisent C, Batorova A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010. [Epub ahead of print]
   Google Scholar
• Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfus 2010;8(4):288-91
   PubMedGoogle Scholar
• Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006;107(1):46-51
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007;109(11):4693-7
   PubMed Web of Science ®Google Scholar
• Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007;13(2):149-55
   PubMed Web of Science ®Google Scholar
• Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 2012;81(1):82-93
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9(4):418-35
   PubMed Web of Science ®Google Scholar
• Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010;8(6):1256-65
   PubMed Web of Science ®Google Scholar
• Scharrer I, Ehrlich HJ. Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges? Haemophilia 2004;10(2):197-8
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013;368(3):231-9
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007;13(suppl 5):65-8
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov. Study of first time immunotolerance induction in severe hemophilia A patients with inhibitor at high risk of failure: comparison with FVIII concentrates with or without Von Willebrand Factor - RES.I.S.T. Available from: www.clinicaltrials.gov/ct2/show/NCT01051544 [Last accessed 19 March 2013]
   Google Scholar
• Kaveri S, Mannucci PM, Kurth MH, et al. von Willebrand factor: what is its role in the immune response in haemophilia? Haemophilia 2011;17(1):e235-8
   Web of Science ®Google Scholar
• Lacroix-Desmazes S, Repesse Y, Kaveri SV, Dasgupta S. The role of VWF in the immunogenicity of FVIII. Thromb Res 2008;122(Suppl 2):S3-6
   Google Scholar
• Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009;7(9):1446-56
   PubMed Web of Science ®Google Scholar
• Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011;9(11):2180-92
   PubMed Web of Science ®Google Scholar
• Parker ET, Craddock HN, Barrow RT, Lollar P. Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII. J Thromb Haemost 2004;2(4):605-11
   PubMed Web of Science ®Google Scholar
• Iorio A, Marcucci M, Makris M. Concentrate-related inhibitor risk: is a difference always real? J Thromb Haemost 2011;9(11):2176-9
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Factor VIII inhibitors in previously treated hemophilic patients. J Thromb Haemost 2011;9(11):2328-9
   PubMed Web of Science ®Google Scholar
• Turecek PL, Bossard MJ, Graninger M, et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012;32(Suppl 1):S29-38
   PubMed Web of Science ®Google Scholar
• Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010;116(2):270-9
   PubMed Web of Science ®Google Scholar
• Coyle T, Reding M, Lin J, et al. An open-label phase I study to evaluate the pharmacokinetics and safety profile of Bay 94-9027, a PEGylated B-domain-deleted recombinant factor VIII, in previously treated patients with severe hemophilia A. Haemophilia 2012;18(Suppl 3):Abstract FP-MO-03.02-03
   Google Scholar
• Agerso H, Stennicke HR, Pelzer H, et al. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia 2012;18(6):941-7
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013;11(4):670-8
   PubMed Web of Science ®Google Scholar
• Rath T, Baker K, Dumont JA, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012;119(13):3031-7
   PubMed Web of Science ®Google Scholar
• Biogen Idec. Biogen Idec and Sobi announce positive top-line results from phase 3 study investigating long-lasting recombinant factor VIII FC fusion protein in Hemophilia A. [Press release 13 October 2012]
   Google Scholar
• Fischer K, Pendu R, van Schooten CJ, et al. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE 2009;4(8):e6745
   Web of Science ®Google Scholar
• Tang L, Leong L, Sim D, et al. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. Haemophilia 2013;19(4):539-45
   PubMed Web of Science ®Google Scholar
• Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res 2013;131(Suppl 2):S2-6
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012;119(3):666-72
   PubMed Web of Science ®Google Scholar
• Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012;120(12):2405-11
   PubMed Web of Science ®Google Scholar
• Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011;118(10):2695-701
   PubMed Web of Science ®Google Scholar
• DePalma AF. Hemophilic arthropathy. Clin Orthop Relat Res 1967;52:145-65
   PubMedGoogle Scholar
• Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977;59(3):287-305
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007;110(3):815-25
   PubMed Web of Science ®Google Scholar
• Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004;104(12):3494-500
   PubMed Web of Science ®Google Scholar
• Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965;77(Suppl):3-132
   Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357(6):535-44
   PubMed Web of Science ®Google Scholar
• Antunes SV, Vicari P, Cavalheiro S, Bordin JO. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 2003;9(5):573-7
   PubMed Web of Science ®Google Scholar
• National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available from: www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007 [Last accessed 4 November 2007]
   Google Scholar
• Berntorp E, Boulyjenkov V, Brettler D. Modern treatment of haemophilia. Bull World Health Organ 1995;73(5):691-701
   PubMed Web of Science ®Google Scholar
• Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med 1997;241(5):395-400
   PubMed Web of Science ®Google Scholar
• Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9(suppl 1):1-4
   PubMed Web of Science ®Google Scholar
• Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010;16(2):256-62
   PubMed Web of Science ®Google Scholar
• Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004;10(2):134-46
   PubMed Web of Science ®Google Scholar
• Auerswald G, Kurnik K, Blatny J, Reininger A. The EPIC study: a clinical trial to assess whether early low dose prophylaxis in the absence of immunological danger signals reduces inhibitor incidence in previously untreated patients (PUPs) with hemophilia A. Blood 2013;122(21):Abstract 576
   Web of Science ®Google Scholar
• Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002;99(7):2337-41
   PubMed Web of Science ®Google Scholar
• Astermark J. When to start and when to stop primary prophylaxis in patients with severe haemophilia. Haemophilia 2003;9(Suppl 1):32-6. discussion 37
   PubMedGoogle Scholar
• van Dijk K, Fischer K, van der Bom JG, et al. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005;130(1):107-12
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Franchini M, Coppola A, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008;14(5):945-51
   PubMed Web of Science ®Google Scholar
• Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236(4):391-9
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Nuss R, Geraghty S, et al. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994;47(2):113-17
   PubMed Web of Science ®Google Scholar
• Noone D, O’Mahony B, van Dijk JP, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013;19(1):44-50
   PubMed Web of Science ®Google Scholar
• Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009;15(5):1014-21
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lambert T, Street A, Aledort L. Tertiary prophylaxis in adults: is there a rationale? Haemophilia 2012;18(5):722-8
   PubMed Web of Science ®Google Scholar
• Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004;10(Suppl 1):63-70
   PubMed Web of Science ®Google Scholar
• Fischer K, Pouw ME, Lewandowski D, et al. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica 2011;96(5):738-43
   PubMed Web of Science ®Google Scholar
• Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002;8(6):753-60
   PubMed Web of Science ®Google Scholar
• Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006;4(6):1228-36
   PubMed Web of Science ®Google Scholar
• Fischer K, Steen Carlsson K, Petrini P, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013;122(7):1129-36
   PubMed Web of Science ®Google Scholar
• Kraft J, Blanchette V, Babyn P, et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012;10(12):2494-502
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012;119(2):612-18
   PubMed Web of Science ®Google Scholar
• Collins PW, Fischer K, Morfini M, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011;17(1):2-10
   PubMed Web of Science ®Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012;10(3):359-67
   PubMed Web of Science ®Google Scholar
• Khair K, Lawrence K, Butler R, et al. Assessment of Treatment Practice Patterns for Severe Hemophilia A: a Global Nurse Perspective. Acta Haematol 2008;119(2):115-23
   PubMed Web of Science ®Google Scholar
• Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia 2012;18(3):e140-53
   Web of Science ®Google Scholar
• Robert P. Projected trends in coagulation factors supply and demand. Presented at the World Federation of hemophilia 6th global forum on the safety and supply of treatment products for bleeding disorders; 24–25 September 2009; Montrea, Canada
   Google Scholar
• Skinner MW. WFH: closing the global gap--achieving optimal care. Haemophilia 2012;18(Suppl 4):1-12
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. Report on the Annual Global Survey 2010. World Federation of Hemophilia; Montreal, QC, Canada: 2011
   Google Scholar